You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Moodys
Baxter
AstraZeneca
Johnson and Johnson

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,010,323

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,010,323 protect, and when does it expire?

Patent 9,010,323 protects SPIRIVA and is included in one NDA.

This patent has seventeen patent family members in ten countries.

Summary for Patent: 9,010,323
Title:Inhaler and sieve for an inhaler
Abstract: An inhaler (1) includes a sieve part (9) for administrating powdered substances such as medical substances. The inhaler (1) includes a suction air channel (6) leading to a mouthpiece (4), a substance supply container (8) that is moveable inside a receiving chamber (7) and the sieve part (9) disposed in the suction air channel (6) between the receiving chamber (7) and the mouthpiece (4). The sieve part includes a retaining edge (10), a sieve area contained in a cross sectional area within the retaining edge (10), and a protruding area (12) that protrudes to one side and has a flat portion (13).
Inventor(s): Haerder; Lukas (Bad Neustadt/Saale, DE), Breuer; Claus (Ennigerloh, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:12/921,447
Patent Claim Types:
see list of patent claims
Delivery;

Drugs Protected by US Patent 9,010,323

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,010,323

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2008 014 025Mar 13, 2008
PCT Information
PCT FiledMarch 11, 2009PCT Application Number:PCT/EP2009/052858
PCT Publication Date:September 17, 2009PCT Publication Number: WO2009/112521

International Family Members for US Patent 9,010,323

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2717275   Start Trial
Canada 2838366   Start Trial
Germany 102008014025   Start Trial
Denmark 2254634   Start Trial
European Patent Office 2254634   Start Trial
European Patent Office 2433665   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKesson
Dow
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.